Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 18, 2000

View Archived Issues

Butyric acid compounds may offer antigen-specific immunotherapy

Aradigm completes phase II trial with AERx delivery of dornase alfa for CF patients

Glucophage XR: once-daily type 2 diabetes drug approved by FDA

Merger of Corixa and Coulter to create comprehensive immunotherapy company

Preliminary human safety and PK/PD findings reported for Z-13752A

Potent Na+/H+ exchange inhibitor TY-12533 displays excellent cardioprotective profile in vivo

Novartis and Bristol-Myers Squibb enter alliance for IBS and autoimmune therapy

Newest TZD approved in Europe for type 2 diabetes

Development of vaccine for genital warts discontinued

Roche creates Basilea Pharmaceutica

Inflammatory disease collaboration announced by Serono and British Biotech

Dimethaid Research seeks approval for topical osteoarthritis treatment in Canada

Second IND filed in Canada for Theratechnologies' GH-releasing analogue

Esperion acquires biotechnology company; LUV program proceeds ahead of schedule

Priority review status issued for Xyrem

NIH supports HIV research at Progenics with funding

Molecumetics and Athersys to codevelop small-molecule drugs

Bimoclomol derivative with improved pharmacological profile identified at Biorex

Peptide derivatives from Aventis modulate basement membrane synthesis

U.K. researchers patent glycopeptides that enhance T-cell proliferation

Nortran's new ion channel blockers useful as antiarrhythmics

New agents for herpesvirus infections described by Bayer

GnRH antagonists as a focus of research at Merck

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 7, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 7, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.